

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Grant-Huerta Yanina</u> (Last) (First) (Middle) <u>C/O ATARA BIOTHERAPEUTICS, INC.</u> <u>1280 RANCHO CONEJO BOULEVARD</u> (Street) <u>THOUSAND</u> <u>CA</u> <u>91320</u> <u>OAKS</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/31/2025</u>	3. Issuer Name and Ticker or Trading Symbol <u>Atara Biotherapeutics, Inc. [ATRA]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Accounting Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>39,285</u> ⁽¹⁾⁽²⁾	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Employee Stock Option (Right to Buy)</u>	<u>04/06/2024</u>	<u>04/30/2030</u>	<u>Common Stock</u>	<u>800</u>	<u>198</u>	<u>D</u>	
<u>Employee Stock Option (Right to Buy)</u>	<u>03/01/2025</u>	<u>02/28/2033</u>	<u>Common Stock</u>	<u>1,100</u>	<u>97.75</u>	<u>D</u>	
<u>Employee Stock Option (Right to Buy)</u>	<u>(3)</u>	<u>02/28/2033</u>	<u>Common Stock</u>	<u>550</u>	<u>97.75</u>	<u>D</u>	
<u>Employee Stock Option (Right to Buy)</u>	<u>07/31/2024</u>	<u>01/05/2034</u>	<u>Common Stock</u>	<u>275</u>	<u>11</u>	<u>D</u>	

Explanation of Responses:

1. Includes an aggregate 33,840 restricted stock units ("RSUs"), which are comprised of: (i) 51 RSUs that vest on November 15, 2025; (ii) 3,614 RSUs that vest as to 1/4th of the shares on May 15, 2025, and each of the next three (3) Quarterly Vesting Dates (as defined herein); (iii) 1,125 RSUs that vest as to 1/5th of the shares on May 15, 2025, and each of the next four (4) Quarterly Vesting Dates; and (iv) 29,050 RSUs that vest as to 1/8th of the shares on May 15, 2025, and each of the next seven (7) Quarterly Vesting Dates, each of which is subject to the reporting person's continuous service.
2. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the "Quarterly Vesting Date" shall be the first (1st) business day after such date.
3. 1/12th of the shares subject to the stock option vested and became exercisable on April 1, 2025, and the remaining shares vest in equal monthly installments over the following eleven (11) months, subject to the reporting person's continuous service.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ John Chao, Attorney-in-Fact for Yanina Grant-Huerta 04/10/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these present, that the undersigned, as a Section 16 reporting person of Atara Biotherapeutics, Inc. (the "Company"), hereby constitutes and appoints each of John Chao and Katie Kirk, or either of them acting individually, and with full power of substitution, the undersigned's true and lawful attorneys-in-fact to:

- I. Complete and execute Forms 3, 4 and 5, Forms 144, and other forms and all amendments thereto, as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, Rule 144 under the Securities Act of 1933 ("Rule 144"), or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company;
2. Enroll the undersigned in the SEC's enhanced Electronic Data Gathering, Analysis, and Retrieval system ("EDGAR Next"), and serve as an Account Administrator for the undersigned's account in EDGAR Next; and
3. Do and perform any and all acts on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or Form 144, or Form ID with the Securities and Exchange Commission (the "SEC"), any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended) or Rule 144.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5, and Forms 144 with the SEC with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of April 3rd, 2025.

Signature: /s/ Yanina Grant-Huerta
Yanina Grant-Huerta

Notary Signature and Seal to be Placed Here:

/s/ Tracy Lynn Watz
